Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2B | P67870 | 19/20 | 0.68 |
| ▸ | CSNK2A2 | P19784 | 17/20 | 0.68 |
| ▸ | PIM1 | P11309 | 18/20 | 0.59 |
| ▸ | PIM3 | Q86V86 | 16/20 | 0.59 |
| ▸ | PIM2 | Q9P1W9 | 16/20 | 0.59 |
| ▸ | CDC7 | O00311 | 7/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1860491 | 1.00 | CSNK2B (0.68) | CSNK2BCSNK2A2PIM1PIM3PIM2 | |
| SCHEMBL12661332 | 0.89 | CSNK2B (0.53) | CSNK2BCSNK2A2PIM1PIM3PIM2 | |
| SCHEMBL1853950 | 0.86 | CSNK2B (0.64) | CSNK2BCSNK2A2PIM1PIM3PIM2 | |
| SCHEMBL1849875 | 0.85 | CSNK2B (0.53) | CSNK2BCSNK2A2PIM1PIM3PIM2 | |
| SCHEMBL1853351 | 0.83 | CSNK2B (0.60) | CSNK2BCSNK2A2PIM1PIM3PIM2 | |
| SCHEMBL1850875 | 0.83 | CSNK2B (0.55) | CSNK2BCSNK2A2PIM1PIM3PIM2 | |
| SCHEMBL1852394 | 0.83 | CSNK2B (0.55) | CSNK2BCSNK2A2PIM1PIM3PIM2 | |
| SCHEMBL1849777 | 0.82 | CSNK2B (0.58) | CSNK2BCSNK2A2PIM1PIM3PIM2 | |
| SCHEMBL1851083 | 0.81 | CSNK2B (0.65) | CSNK2BCSNK2A2PIM1PIM3PIM2 | |
| SCHEMBL1850752 | 0.80 | CSNK2B (0.56) | CSNK2BCSNK2A2PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | claimed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | claimed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | CSNK2B 350/4885CSNK2A2 906/4885PIM1 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.